By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen Biotech Inc. 

800 Ridgeview Drive

Horsham  Pennsylvania  19044  U.S.A.
Phone: 888-227-5624 Fax: n/a


SEARCH JOBS








Company News
Adaptive Biotech Announces A Collaboration With Janssen Biotech (JNJ) To Use The clonoSEQ? Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX? Multiple Myeloma Trials 6/22/2017 12:39:44 PM
Adaptive Biotech Announces A Collaboration With Janssen Biotech (JNJ) To Use The Clonoseq Assay To Measure Minimal Residual Disease In Ongoing And Future DARZALEX Multiple Myeloma Trials 6/21/2017 7:19:57 AM
Janssen Biotech (JNJ) Release: DARZALEX (daratumumab) Approved By The U.S. FDA In Combination With Pomalidomide And Dexamethasone For Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies 6/19/2017 8:01:37 AM
Pulmatrix (PULM) Licenses Novel Drug Candidates From RespiVert Ltd., A Wholly Owned Subsidiary Of Janssen Biotech (JNJ) 6/13/2017 7:37:21 AM
Innovative Targeting Solutions Collaboration With Janssen Biotech (JNJ) Achieves Multiple Milestones 5/24/2017 8:22:24 AM
Janssen Biotech (JNJ) Release: New Data Shows STELARA (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease 2/17/2017 6:24:00 AM
X-Chem Expands Collaboration With Janssen Biotech (JNJ) In Inflammatory Diseases 2/15/2017 8:08:59 AM
Ablexis Announces Perpetual License Agreement For Alivamab Mouse With Janssen Biotech (JNJ) 2/14/2017 11:07:04 AM
Sebia Signs Agreement With Janssen Biotech (JNJ) To Develop A Multiple Myeloma IVD Test 1/30/2017 9:01:09 AM
Janssen Biotech (JNJ) Release: IMBRUVICA (Ibrutinib) Approved By FDA For Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy And Have Received At Least One Prior Anti-CD20-Based Therapy 1/19/2017 7:21:54 AM
12345678910...
//-->